Observational studyMedicine2025
Risk factors for coronary artery disease progression: A retrospective cohort study of clinical and biochemical predictors.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to identify clinical and biochemical predictors of coronary artery disease (CAD) progression in patients undergoing routine cardiovascular evaluation. A retrospective cohort study was conducted involving 183 patients with confirmed CAD (92 with progression and 91 without progression). Clinical data, echocardiographic parameters, and laboratory biomarkers were collected at baseline. CAD progression was assessed based on repeat coronary angiography after a follow-up period. Multivariate logistic regression was used to identify independent predictors of CAD progression. The predictive accuracy of the model was evaluated using the area under the receiver operating characteristic curve), and model fit was assessed using the Hosmer-Lemeshow test. Elevated interleukin-6 levels (OR = 3.051, 95% confidence interval: 1.164-7.999, P = .023) and triglycerides (approaching significance, odds ratio = 1.126, 95% confidence interval: 0.980-1.293, P = .093) were identified as key predictors of CAD progression. The final model showed good discrimination with an area under the receiver operating characteristic curve of 0.701 and an acceptable fit (Hosmer-Lemeshow test: P = .078). Elevated interleukin-6 and triglycerides levels are significant or near-significant predictors of CAD progression. These findings suggest that inflammatory and lipid biomarkers play critical roles in disease progression and may serve as valuable targets for therapeutic interventions in high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.